Skip to main content
WWB
NASDAQ Life Sciences

Director Stampacchia Buys $29.75M of Windward Bio IPO Shares at $17.00

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$21.72
Mkt Cap
$1.314B
52W Low
$18.35
52W High
$33.985
52W Position info
18% above low
Off High info
36% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

WWB sits 18% above its 52-week low of $18.35.

Summary

Windward Bio director Otello Stampacchia's Omega funds bought 1.75M shares at $17.00 for $29.75M in the IPO, alongside a 3.59M-share preferred conversion into common stock.


Key Events · Ownership and Investor Activity · WWB

  • Director's Funds Buy $29.75M at IPO Price

    Omega Fund VII and Omega Fund VIII each acquired 875,000 shares at $17.00 on 2026-11-16, totaling 1,750,000 shares for $29,750,000.

  • Preferred Converts 1:1 Into Common

    Immediately prior to the IPO closing, 3,588,520 Series A and Series B preferred shares converted into common on a 1-to-1 basis, leaving the funds with zero preferred.

  • Post-Transaction Indirect Stake 8.93M Shares

    Following the purchase and conversion, the Omega funds indirectly hold 8,927,040 common shares; the reporting person disclaims beneficial ownership beyond his pecuniary interest.

  • Follows $251.2M IPO and Sanofi Placement

    The purchase came at the $17.00 IPO price set on 2026-11-12, in the same window as the IPO close and concurrent Sanofi private placement that raised $251.2M gross.


Analysis · WWB · Life Sciences

Why it matters: a fund affiliated with director Otello Stampacchia (Omega Fund VII and VIII) put $29.75M of real money into 1.75M shares at the $17.00 IPO price, an anchor order rather than an option exercise. The same filing shows 3.59M preferred shares converting 1:1 into common immediately before the IPO close, which is mechanical pre-IPO cleanup rather than new dilution. The purchase is the meaningful part: a board member buying at the offer price alongside the $251.2M IPO and Sanofi private placement shows insider alignment at the exact level outside investors paid.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, WWB was trading at $21.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $18.35 to $33.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

WWB - Latest Insights

WWB
Nov 16, 2026, 5:22 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $30.04
Real-time Price: $22.42 info
Change: -$7.62 (-25%) info
Market Cap: $1.314B info
WWB
Nov 16, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $30.04
Real-time Price: $22.42 info
Change: -$7.62 (-25%) info
Market Cap: $1.314B info
WWB
Nov 12, 2026, 6:19 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: N/A
Real-time Price: $22.42 info
Change: N/A info
Market Cap: $1.314B info